Found: 7
Select item for more details and to access through your institution.
Analysis of Hornozygous TGFβ1 Null Mouse Embryos Demonstrates Defects in Yolk Sac. Vasculogenesis and Hematopoiesis.
- Published in:
- Annals of the New York Academy of Sciences, 1995, v. 752, n. 1, p. 300, doi. 10.1111/j.1749-6632.1995.tb17439.x
- By:
- Publication type:
- Article
Highly selective SYK inhibitor, GSK143, abrogates survival signals in chronic lymphocytic leukaemia.
- Published in:
- British Journal of Haematology, 2018, v. 182, n. 6, p. 927, doi. 10.1111/bjh.14884
- By:
- Publication type:
- Article
Spleen tyrosine kinase ( SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients.
- Published in:
- Experimental Dermatology, 2016, v. 25, n. 5, p. 375, doi. 10.1111/exd.12986
- By:
- Publication type:
- Article
Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: Results of a phase 1a/b randomised double‐blind placebo‐controlled study.
- Published in:
- British Journal of Clinical Pharmacology, 2021, v. 87, n. 12, p. 4797, doi. 10.1111/bcp.14923
- By:
- Publication type:
- Article
A model of skin inflammation in humans leads to a rapid and reproducible increase in the interferon response signature: a potential translational model for drug development.
- Published in:
- Inflammation Research, 2015, v. 64, n. 3/4, p. 171, doi. 10.1007/s00011-015-0795-z
- By:
- Publication type:
- Article
Safety, pharmacokinetics and pharmacodynamics of a topical SYK inhibitor in cutaneous lupus erythematosus: A double‐blind Phase Ib study.
- Published in:
- Experimental Dermatology, 2021, v. 30, n. 11, p. 1686, doi. 10.1111/exd.14253
- By:
- Publication type:
- Article
GSK2646264, a spleen tyrosine kinase inhibitor, attenuates the release of histamine in ex vivo human skin.
- Published in:
- 2019
- By:
- Publication type:
- journal article